Marta Ribes

Marta Ribes

Auto-generated profile, based on publicly available information

Marta Ribes

Barcelona Institute for Global Health, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAlberto L. Garcia-Basteiro
Alberto L. Garcia-Basteiro
GMGemma Moncunill
Gemma Moncunill
MTMarta Tortajada
Marta Tortajada
MVMarta Vidal
Marta Vidal
CGCaterina Guinovart
Caterina Guinovart
CDCarlota Dobaño
Carlota Dobaño
Health care workers (HCW) are a high-risk population to acquire SARS-CoV-2 infection from patients or other fellow HCW. This study aims at estimating the seroprevalence against SARS-CoV-2 in a random sample of HCW from a large hospital in Spain. Of the 578 participants recruited from 28 March to 9 April 2020, 54 (9.3%, 95% CI: 7.1–12.0) were seropositive for IgM and/or IgG and/or IgA against SARS-CoV-2. The cumulative prevalence of SARS-CoV-2 infection (presence of antibodies or past or current positive rRT-PCR) was 11.2% (65/578, 95% CI: 8.8–14.1). Among those with evidence of past or current infection, 40.0% (26/65) had not been previously diagnosed with COVID-19. Here we report a relatively low seroprevalence of antibodies among HCW at the peak of the COVID-19 epidemic in Spain. A large proportion of HCW with past or present infection had not been previously diagnosed with COVID-19, which calls for active periodic rRT-PCR testing in hospital settings.

6 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NONatalia Ortega
Natalia Ortega
MRMarta Ribes
Marta Ribes
MVMarta Vidal
Marta Vidal
RRRocío Rubio
Rocío Rubio
RARuth Aguilar
Ruth Aguilar
CDCarlota Dobaño
Carlota Dobaño
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.

24 April 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MRMarta Ribes
Marta Ribes
CCCarlos Chaccour
Carlos Chaccour
GMGemma Moncunill
Gemma Moncunill

8 November 2025 in eClinicalMedicine
Verified
Journal Article
Open access
CCCarlos Chaccour
Carlos Chaccour
PNPatricia Nicolas
Patricia Nicolas
SMSamuel Martinho
Samuel Martinho
HMHansel Mundaca
Hansel Mundaca
EEEldo Elobolobo
Eldo Elobolobo
FSFrancisco Saute
Francisco Saute
Endectocides are a novel vector control tool that reduce the survival and fertility of blood sucking arthropods that feed upon treated humans or animals. Ivermectin mass drug administration is under evaluation as a complementary strategy for malaria vector control. The BOHEMIA consortium conducted two cluster-randomized trials, one in Mozambique, reported here and one in Kenya, reported elsewhere. The trial was conducted in Mopeia, a highly endemic district in Zambezia province, with perennial transmission and over 70% coverage of both indoor residual spraying and long-lasting insecticidal nets. As per protocol, we planned to randomise 53 clusters per arm (1:1:1), to receive either (a) single 400 mcg/kg dose of ivermectin to all eligible humans, once a month for three months, (b) the same ivermectin treatment to eligible humans plus injectable ivermectin (1% solution) to all eligible pigs (300 mcg/kg) and cattle (200 mcg/kg) in the cluster once a month for three months or (c) albendazole (400 mg), to serve as control, to eligible humans, following the same schedule. The primary efficacy outcome was malaria incidence of infections determined by RDT in a cohort of children under five years that was followed monthly for six months starting with the first mass drug administration round. Dual HRP-2 and pLDH rapid diagnostic tests were used in an attempt to discriminate incident infections. The rate of adverse events was captured in all treated individuals. The analysis was done using generalized estimating equations following intention-to-treat. Before the start of mass drug administration, the study site experience floods caused by the Gombe cyclone, resulting in severe logistical constrains and the loss of 57 clusters. We present a complete case analysis of the remaining clusters. The study ran between march 17 and October 18, 2022. Overall, a total of 22,724 participants from a reduced number of 100 clusters were enrolled. Six months after the first treatment round, the malaria infection incidence was comparable between all three arms with adjusted incidence rate ratio values of 0.99 (95% CI, 0.86–1.14, P > 0.9) and 1.05 (95% CI, 0.87–1.27, P = 0.6) between the human-only and control group and the human and livestock and control group respectively. The rate of severe adverse events per 10,000 treatments was not significantly different between the combined ivermectin arms and the control (IRR = 1.29; 95% CI 0.62–2.68). This trial did not meet implementation goals due to operational challenges including low coverage, displaced populations and delayed start of drug distribution which render the efficacy data inconclusive. However, important aspects regarding the action of endectocides at community level which could be key for implementation are described. Additionally, valuable data regarding safety were collected (ClinicalTrials.gov number, NCT04966702). The study was funded and supported by Unitaid under the “BOHEMIA” grant.

19 March 2025 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MRMarta Ribes
Marta Ribes
FHFizaa Halani
Fizaa Halani
AAAbdala Atumane
Abdala Atumane
MAMilagre Andurage
Milagre Andurage
EEEldo Elobolobo
Eldo Elobolobo
CCCarlos Chaccour
Carlos Chaccour
Background: Noma is a neglected tropical disease primarily affecting children living in poverty. Despite being preventable and treatable with readily accessible medicines, an estimated 90% of patients die due to lack of access to prompt and appropriate care. Methodology and principal findings: Primary, secondary and quaternary health facilities were visited on a convenience-sampling basis in Zambezia Province, central Mozambique. Health professionals were invited to participate on a quota-sampling basis, and were administered a questionnaire including open and close-ended questions assessing their oral health practices, theoretical knowledge on noma and attitudes towards receiving a noma training. A total of 41 health professionals from 23 different health facilities participated in the study. Of these, 59% were aware of noma, and 26.8% reported having personally attended to an acute noma patient. However, their knowledge of noma’s clinical characteristics and management was poor, especially in its early stages. Only 12% correctly diagnosed noma at stage 1, and 5% at stage 2. University-level professionals had a significantly better understanding of the disease than nurses and technicians. All participants were keen on receiving specific noma training. Conclusions: Noma management competencies in Zambezia are extremely low, particularly among nurses and medical technicians, who serve as the first point of care for noma patients. There is an urgent need to implement comprehensive training programs across all levels of Mozambican healthcare providers, to prevent further avoidable deaths and reduce the severe outcomes associated with delayed treatment.

23 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
NONatalia Ortega
Natalia Ortega
MRMarta Ribes
Marta Ribes
MVMarta Vidal
Marta Vidal
RRRocío Rubio
Rocío Rubio
RARuth Aguilar
Ruth Aguilar
CDCarlota Dobaño
Carlota Dobaño
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and its determinants, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E,NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed-up for 6 months (N = 578). Seroprevalence increased over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, were stable over time, except IgG to nucleocapsid antigen and IgM levels that waned. After the peak response, anti-spike antibody levels increased from ∼150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. Pre-existing antibodies to alpha-HCoV were lower in individuals who subsequently seroconverted for SARS-CoV-2. IgG and IgA to HCoV were significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.